WuXi Biologics (2269)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 16 Oct 2026
Key indicators
| Last close | HKD 48.20 |
|---|---|
| 52-week range | 28.48 – 58.00 |
| Return, 1 month / 3 months | −3.5% / +26.0% |
| Return, 1 year / 3 years | +14.8% / +11.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 39 |
| Volatility (1 year) | 45.3% |
| Worst drawdown (1 year) | -28.7% |
| Average daily value traded | 1,752.34M HKD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
WuXi Biologics is a contract research, development and manufacturing organisation serving the biopharmaceutical industry. The company helps drug developers discover, develop and manufacture biologic medicines, including antibody-based therapies, from its base in China for customers around the world. Its services span early-stage research through clinical and commercial production, and it works with both small biotech firms and larger pharmaceutical companies that need external development and manufacturing capacity for their biologic candidates.
On this site WuXi Biologics appears as a stock on the Hong Kong Stock Exchange (Hong Kong), code 2269, with prices in Hong Kong dollars (HKD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
WuXi Biologics (2269) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 48.20 on 16 October 2026.
Its price-based Market X-Ray is 85 out of 100 (a strong price profile), ranking 22 of 3,157 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.8% and over the last three months it rose 26.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 89 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 22.6% | ||
| From 52-week high | -16.8% | ||
| Momentum | 85 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 26.0% | ||
| 6-month return | 29.6% | ||
| 12-month return, skipping the last month | 18.9% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 45.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.7% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 1,752.34M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −10.5% |
|---|---|
| 1 month | −3.5% |
| 3 months | +26.0% |
| 6 months | +29.6% |
| 1 year | +14.8% |
| 3 years | +11.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 50.34 / 39.32 |
|---|---|
| Golden / death cross (60 days) | Golden, 51 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.54 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.